skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2

Abstract

Highlights: • miR-30a represses Eya2 expression by binding to the 3′-untranslated region of Eya2. • The miR-30a/EYA2 axis regulates breast cancer cell proliferation and migration. • The miR-30a/EYA2 axis modulates G1/S cell cycle progression. • The miR-30a/EYA2 axis is dysregulated in breast cancer patients. - Abstract: Eye absent (Eya) proteins are involved in cell fate determination in a broad spectrum of cells and tissues. Aberrant expression of Eya2 has been documented in a variety of cancers and correlates with clinical outcome. However, whether microRNAs (miRNAs) can regulate Eya2 expression remains unknown. Here, we show that miR-30a represses Eya2 expression by binding to the 3′-untranslated region of Eya2. Overexpression of Eya2 in miR-30a-transfected breast cancer cells effectively rescued the inhibition of cell proliferation and migration caused by miR-30a. Knockdown of Eya2 by small-interfering RNA (siRNA) in breast cancer cells mimicked the effect induced by miR-30a and abolished the ability of miR-30a to regulate breast cancer cell proliferation and migration. The miR-30a/Eya2 axis could regulate G1/S cell cycle progression, accompanied by the modulation of expression of cell cycle-related proteins, including cyclin A, cyclin D1, cyclin E, and c-Myc. Moreover, miR-30a expression was downregulated in breast cancer patients, and negatively correlated with Eya2,more » which was upregulated in breast cancer patients. These data suggest that the miR-30a/Eya2 axis may play an important role in breast cancer development and progression and that miR-30a activation or Eya2 inhibition may be a useful strategy for cancer treatment.« less

Authors:
 [1];  [2];  [3];  [2];  [4];  [1]; ; ;  [2];  [1];  [5];  [4];  [2];  [1]
  1. Department of Endocrinology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing (China)
  2. Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing (China)
  3. Department of Nuclear Medicine, Peking University First Hospital, Beijing (China)
  4. Department of General Surgery, 307 Hospital of PLA, Beijing (China)
  5. Beijing Institute of Radiation Medicine, Beijing (China)
Publication Date:
OSTI Identifier:
22416302
Resource Type:
Journal Article
Journal Name:
Biochemical and Biophysical Research Communications
Additional Journal Information:
Journal Volume: 445; Journal Issue: 2; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ANIMAL TISSUES; CELL CYCLE; CELL PROLIFERATION; INHIBITION; MAMMARY GLANDS; MIGRATION; NEOPLASMS; PATIENTS; PROTEINS; RNA

Citation Formats

Fu, Jing, Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, Xu, Xiaojie, Kang, Lei, Zhou, Liying, Wang, Shibin, Lu, Juming, Cheng, Long, Fan, Zhongyi, Yuan, Bin, Tian, Peirong, Zheng, Xiaofei, Yu, Chengze, Ye, Qinong, and Lv, Zhaohui. miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. United States: N. p., 2014. Web. doi:10.1016/J.BBRC.2014.01.174.
Fu, Jing, Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, Xu, Xiaojie, Kang, Lei, Zhou, Liying, Wang, Shibin, Lu, Juming, Cheng, Long, Fan, Zhongyi, Yuan, Bin, Tian, Peirong, Zheng, Xiaofei, Yu, Chengze, Ye, Qinong, & Lv, Zhaohui. miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. United States. https://doi.org/10.1016/J.BBRC.2014.01.174
Fu, Jing, Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, Xu, Xiaojie, Kang, Lei, Zhou, Liying, Wang, Shibin, Lu, Juming, Cheng, Long, Fan, Zhongyi, Yuan, Bin, Tian, Peirong, Zheng, Xiaofei, Yu, Chengze, Ye, Qinong, and Lv, Zhaohui. 2014. "miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2". United States. https://doi.org/10.1016/J.BBRC.2014.01.174.
@article{osti_22416302,
title = {miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2},
author = {Fu, Jing and Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing and Xu, Xiaojie and Kang, Lei and Zhou, Liying and Wang, Shibin and Lu, Juming and Cheng, Long and Fan, Zhongyi and Yuan, Bin and Tian, Peirong and Zheng, Xiaofei and Yu, Chengze and Ye, Qinong and Lv, Zhaohui},
abstractNote = {Highlights: • miR-30a represses Eya2 expression by binding to the 3′-untranslated region of Eya2. • The miR-30a/EYA2 axis regulates breast cancer cell proliferation and migration. • The miR-30a/EYA2 axis modulates G1/S cell cycle progression. • The miR-30a/EYA2 axis is dysregulated in breast cancer patients. - Abstract: Eye absent (Eya) proteins are involved in cell fate determination in a broad spectrum of cells and tissues. Aberrant expression of Eya2 has been documented in a variety of cancers and correlates with clinical outcome. However, whether microRNAs (miRNAs) can regulate Eya2 expression remains unknown. Here, we show that miR-30a represses Eya2 expression by binding to the 3′-untranslated region of Eya2. Overexpression of Eya2 in miR-30a-transfected breast cancer cells effectively rescued the inhibition of cell proliferation and migration caused by miR-30a. Knockdown of Eya2 by small-interfering RNA (siRNA) in breast cancer cells mimicked the effect induced by miR-30a and abolished the ability of miR-30a to regulate breast cancer cell proliferation and migration. The miR-30a/Eya2 axis could regulate G1/S cell cycle progression, accompanied by the modulation of expression of cell cycle-related proteins, including cyclin A, cyclin D1, cyclin E, and c-Myc. Moreover, miR-30a expression was downregulated in breast cancer patients, and negatively correlated with Eya2, which was upregulated in breast cancer patients. These data suggest that the miR-30a/Eya2 axis may play an important role in breast cancer development and progression and that miR-30a activation or Eya2 inhibition may be a useful strategy for cancer treatment.},
doi = {10.1016/J.BBRC.2014.01.174},
url = {https://www.osti.gov/biblio/22416302}, journal = {Biochemical and Biophysical Research Communications},
issn = {0006-291X},
number = 2,
volume = 445,
place = {United States},
year = {Fri Mar 07 00:00:00 EST 2014},
month = {Fri Mar 07 00:00:00 EST 2014}
}